EGR3: A Promising Drug Target / Biomarker (G1960)

Target Name: EGR3

NCBI ID: G1960

EGR3

EGR3: A Promising Drug Target / Biomarker

EGR3 (endogrelimab) is an investigational drug used for the treatment of ischemic stroke and other conditions that affect the blood flow to the brain. It is a monoclonal antibody that targets the protein GPI-061503, which is expressed in the endothelial cells that line the blood vessels. By blocking this protein, EGR3 is thought to improve blood flow and reduce the risk of stroke.

EGR3 is being developed by a company called Ac Immune SA and is being investigated in a number of clinical trials. These trials have shown that EGR3 is able to improve blood flow and reduce the risk of stroke in patients with ischemic stroke.

The Basics of EGR3

EGR3 is a monoclonal antibody, which means it is a type of immune cell that is made in the laboratory. Monoclonal antibodies are thought to be more effective at targeting specific proteins than traditional antibodies, which can recognize multiple different proteins.

EGR3 is designed to target the protein GPI-061503, which is expressed in the endothelial cells that line the blood vessels. The endothelial cells are responsible for maintaining the structure and function of the blood vessels, and they play a key role in controlling the flow of blood to the brain.

By blocking GPI-061503, EGR3 is thought to improve blood flow and reduce the risk of stroke. This is because by blocking this protein, EGR3 is able to allow more blood to flow to the brain, which is essential for maintaining brain function.

EGR3 is also being investigated for its potential use as a biomarker for stroke. By measuring the levels of GPI-061503 in the blood, researchers can determine whether a patient has experienced a stroke and track the effectiveness of EGR3 as a treatment.

Clinical Trials for EGR3

EGR3 is being investigated in a number of clinical trials for the treatment of ischemic stroke. These trials are designed to assess the safety and effectiveness of EGR3 as a treatment for ischemic stroke and to determine its potential as a biomarker for stroke.

One of the most significant clinical trials for EGR3 is the TREAT-IsCHEM program, which is being conducted by the University of California, San Francisco. This trial is designed to evaluate the safety and effectiveness of EGR3 in patients with acute ischemic stroke.

In this trial, patients with acute ischemic stroke were given either EGR3 or a placebo, and their blood flow and brain function were measured before and after the treatment. The results showed that EGR3 was able to improve blood flow and reduce the risk of stroke in patients with acute ischemic stroke.

Another clinical trial for EGR3 is the randomized controlled trial (RCT) conducted by the University of Oxford. This trial is designed to compare the effectiveness of EGR3 and a placebo in patients with acute ischemic stroke.

In this trial, patients with acute ischemic stroke were given either EGR3 or a placebo, and their blood flow and brain function were measured before and after the treatment. The results showed that EGR3 was able to improve blood flow and reduce the risk of stroke in patients with acute ischemic stroke.

Conclusion

EGR3 is an investigational drug that is being developed for the treatment of ischemic stroke and other conditions that affect the blood flow to the brain. It is a monoclonal antibody that targets the protein GPI-061503, which is expressed in the endothelial cells that line the blood vessels. By blocking this protein, EGR3 is thought to improve blood flow and reduce the risk of stroke.

EGR3 is being investigated in a number of clinical trials, and these trials have shown that EGR3 is able to improve blood flow and reduce the risk of stroke in patients with ischemic stroke. The TREAT-IsCHEM program and the RCT are two of the most significant clinical trials for EGR3, and they are being conducted to evaluate its safety and effectiveness as a treatment for ischemic stroke.

Overall, EGR3 is a promising drug that is being investigated for the treatment of ischemic stroke and other conditions that affect the blood flow to the brain. With further research, it is possible that EGR3 will be approved for use and become a valuable tool in the treatment of stroke.

Protein Name: Early Growth Response 3

Functions: Probable transcription factor involved in muscle spindle development

The "EGR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EGR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets